A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

PepGen, a UK-based developed of therapies for Duchenne muscular dystrophy spun out of University of Oxford, has raised $108m in its initial public offering on Nasdaq. The company had raised some $163m in equity funding prior to its flotation from investors including university venture fund Oxford Science Enterprises.

Quentic, a Germany-based environmental, social and governance management platform spun out of University of Applied Sciences Berlin, has been acquired by AMCS. Financial terms were not disclosed, but Quentic investor High-Tech Gründerfonds noted that it marked its third most profitable exit yet.

Palion Medical, a Norway-based medical device company working on a precision injection product for people suffering from debilitating chronic migraine and cluster headache, agreed to an acquisition by Man & Science, a medical device company focused on headache disorders. Palion is a spinout of Norwegian University of Science & Technology. Financial terms of the acquisition were not disclosed.


Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).